MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    CLOCK varriant correlates to motor fluctuation and sleep disorders in Chinese patients with Parkinson’s disease

    F. Lou, X. Luo, M. Li, Y. Ren (Shenyang, China)

    Objective: This research is to explore whether there is association between Circadian locomotor output cycle kaput (CLOCK) gene polymorphism and biological rhythm disorders of Parkinson’s…
  • 2017 International Congress

    Progression to Parkinson’s disease in carriers of LRRK2 G2019S mutation: a 4-year prospective study with serial dopamine transporter imaging

    J. Infante, M. Sierra, I. Martínez-Rodríguez, P. Sánchjez-Juan, I. González-Aramburu, M. Jimenez-Alonso, A. Sánchez-Rodriguez, I. Banzo (Santander, Spain)

    Objective: To assess whether any of the biomarkers studied (UPDRS-III, SN echogenicity, UPSIT and DaT-SPECT) in a baseline evaluation of a cohort of LRRK2 G2019S asymptomatic…
  • 2017 International Congress

    Characterization of Noncoding Variant(s) Driving Genome-Wide Association of the PARK10 Locus in Autopsy-Proven Parkinson Disease and Controls.

    J. Vance, K. Nuytemans, D. Gveric, L. Gomez, G. Beecham, E. Martin, W. Scott (Miami, FL, USA)

    Objective: Confirm the PARK10 locus as a major GWAS locus in autopsy-confirmed (AC) PD and AC controls and identify potential noncoding variants driving the association. …
  • 2017 International Congress

    Behavioral and psychological symptoms in Parkinson’s disease with SWEDDs

    J. Ahn, H. Kim (Seoul, Republic of Korea)

    Objective: To assess behavioral and psychological symptoms in patients of Parkinson's disease with SWEDDs(PD-SWEDDs.. Background: Behavioral and psychological symptoms are often seen in patients with…
  • 2017 International Congress

    Treatment of Psychosis in Parkinson’s Disease: Evidence-Based Recommendations Versus Actual Clinical Practice

    L.G. Chan, A. Kong, L. Tan (Singapore, Singapore)

    Objective: To examine if actual clinical practice of antipsychotic use in Parkinson's Disease patients are consistent with published evidence-based reviews of treatment recommendations and discuss…
  • 2017 International Congress

    How do Parkinson’s Disease patients manage Ramadan Fasting?

    W. Kamel, P. Damier, J. Al-Hashel (Kuwait, Kuwait)

    Objective: To describe how Parkinson's disease(PD) patients manage Ramadan fasting and the impact of the fasting period on symptoms  Background: Although Ramadan fasting is not…
  • 2017 International Congress

    Tongue strength in Parkinson’s disease.

    H. Kalf, J. van Asperen, F. Tuenter, L. van Vucht, J. Vanderwegen, G. van Nuffelen (Nijmegen, Netherlands)

    Objective: To investigate tongue strength in patients with Parkinson’s disease and the relation with speech and swallowing. Background: Motor disorders in Parkinson’s disease (PD) are…
  • 2017 International Congress

    Comparative Age-Relatedness of Dyskinesia, Dystonia and Ataxia Rating Scales in Healthy Children

    M. Kuiper, R. Brandsma, L. Vrijenhoek, H. Burger, D. Sival (Groningen, Netherlands)

    Objective: In healthy children (4-16 years of age), we aimed to associate DIS scores with age, and compare age-related influences on dyskinesia (DIS), dystonia (BFMDRS)…
  • 2017 International Congress

    VIT-D and Tics Movement Disorder

    N. GEMAWAT (MUMBAI, India)

    Objective: Tics  is  common childhood movement disorder,  with classified variants , typically begin at around 4-5 years of age but often  present  lator at about…
  • 2017 International Congress

    A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations

    S. Ramaswamy, W. Wen, G. Ramaswamy, L. Friedhoff (New York, NY, USA)

    Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations. Background: Nelotanserin is a selective 5HT2A receptor inverse…
  • « Previous Page
  • 1
  • …
  • 106
  • 107
  • 108
  • 109
  • 110
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley